期刊文献+

乌拉地尔与曲美他嗪合用对慢性心力衰竭患者的疗效观察 被引量:1

Clinical Study of Urapidil Combined with Trimetazidine for Treatment of the Chronic Congestive Heart Failure
原文传递
导出
摘要 目的观察乌拉地尔联合曲美他嗪治疗慢性心力衰竭(CHF)的临床疗效。方法将100例心功能(NYHA)III-IV级的CHF患者随机分为乌拉地尔治疗组、曲美他嗪治疗组、乌拉地尔联合曲美他嗪治疗组和对照组,各25例,常规给予血管紧张素转换酶抑制剂、强心、利尿剂等治疗。乌拉地尔治疗组在此基础上连续5d静脉泵入乌拉地尔100~300μg/min。曲美他嗪治疗组持续加用曲美他嗪20mg/次,3次/d,连续3个月。乌拉地尔联合曲美他嗪治疗组除了静脉泵入乌拉地尔100~300μg/min达5d外,还同时加用曲美他嗪20mg/次,3次/d,连续3个月。对照组仅为常规治疗。于治疗前、治疗后5d及治疗后3个月采用超声心动图、6min步行实验(6-MWT)等方法观察4组患者心功能情况,同时检测脑钠肽(BNP)、C反应蛋白(CRP)。结果 3个治疗组心功能改善情况优于对照组,超声心动图指标、6-MWT距离均明显改善,BNP、CRP均降低,两药合用效果更佳。4组均未见明显不良反应。结论乌拉地尔及曲美他嗪均能有效改善CHF患者心功能,降低BNP及CRP,两者合用效果更佳且安全。 Objective To observe the clinical curative effect of Urapidil combined with Trimetazidine on chronic heart failure (CHF). Methods 100 cases of patients with CHF whose cardiac function were III-IV degree(NYHA) were randomly divided into three treatment groups and a control group, 25 cases in each group. Four groups were given conventional treatment, including angiotensin-converting enzyme inhibitors, diuretics and digoxin by oral use. Patients in Urapidil treatment group were treated with Urapidil 100-300 μg/min by venous pump for five days, patients in Trimetazidine treatment group were treated with Trimetazidine 20 mg, 3 times/d, continuous treatment for 3 months, patients in Urapidil combined with Trimetazidine treatment group (the combined treatment group) were treated with both drugs, and those in control group were given conventional treatment. Heart function of all patients were observed by echocardiography, and their exercise endurance were evaluated by 6-minutes walking test (6-MWT) before and after the treatment. The plasma levels of brain natriuretic peptide(BNP) and C-reactive protein (CRP) were detected at the same time. Results The plasma levels of BNP and CRP, heart functin and the distance of 6-MWT were significantly improved after therapy in three treatment groups than in the control group(P0.01), and the improvements in the combined treatment group were better. No obvious side effect was found in four groups. Conclusions Urapidil and Trimetazidine can both significantly decrease the plasma BNP and CRP levels of CHF patients and improve their cardiac function as a safe and reliable treatment. Urapidil combined with Trimetazidine treatment was better.
出处 《中国慢性病预防与控制》 CAS 2012年第4期398-400,共3页 Chinese Journal of Prevention and Control of Chronic Diseases
关键词 心力衰竭 乌拉地尔 曲美他嗪 脑钠肽 C反应蛋白 Heart failure Urapidil Trimetazidine Brain natriuretic peptide C-reactive protein
  • 相关文献

参考文献7

  • 1Buch J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations [ J ]. Adv Ther, 2010,27 ( 7 ) : 426-443.
  • 2Gao D, Ning N, Niu X, et al. Trimetazidine: a recta-analysis ofrandomised controlled trims in heart failure[ J ]. Heart, 2011,97(4) : 278-286.
  • 3Danchin N, Marzilli M, Parkhomenko A, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network recta-analysis[ J ]. Cardiology, 2011,120(2 ) : 59-72.
  • 4Simonenko VB, Stepaniants OS, Teslia AN. Myocardial cytoprotectors, a reserve therapeutic modality for patients with stable angina of effort [J]. Klin Med (Mosk), 2011,89(4) :34-36.
  • 5Yao DK, Jia SQ, Wang L, et al. Therapeutic effect of urapidil on myocardial perfusion in patients with ST-elevation acute coronary syndrome J ]. Eur J Intern Med, 2009,20(2 ) : 152-157.
  • 6Zhang L, Zhang S, Jiang H, et al. Effects of statin therapy on inflam- matory markers in chronic heart failure: a meta-analysis of randomized controlled trials [ J ]. Arch Med Res, 2010,41 ( 4 ) : 464-471.
  • 7Kafkas N, Patsilinakos S, Makrls K, et al. Brain natriuretic peptide: a marker of cardiac dysfunction with ventricular or dual-chamber pacing [ J ]. Acta Cardiol, 2011,66 ( 5 ) :589-594.

同被引文献9

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部